A planned waiver to allow generics and biosimilars firms to manufacture in the European Union (EU) during the term of supplementary protection certificates (SPCs) will include the possibility of stockpiling for ‘day one’ launch within the EU as well as manufacturing for export, according to a compromise agreement approved by the European Parliament’s legal committee, JURI.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?